JPH0324014A - 良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途 - Google Patents
良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途Info
- Publication number
- JPH0324014A JPH0324014A JP2144272A JP14427290A JPH0324014A JP H0324014 A JPH0324014 A JP H0324014A JP 2144272 A JP2144272 A JP 2144272A JP 14427290 A JP14427290 A JP 14427290A JP H0324014 A JPH0324014 A JP H0324014A
- Authority
- JP
- Japan
- Prior art keywords
- dysuria
- oxy
- hydroxy
- naphth
- prostatic hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010013990 dysuria Diseases 0.000 title claims abstract description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims description 6
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 4
- 239000000969 carrier Substances 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 229950005705 naftopidil Drugs 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 abstract description 2
- 206010020880 Hypertrophy Diseases 0.000 abstract description 2
- 208000003455 anaphylaxis Diseases 0.000 abstract description 2
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
- 210000002307 prostate Anatomy 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- KTFZDGGBFILTSA-UHFFFAOYSA-N beta-Sitosterin Natural products CCC(CC)CCC(C)C1CCC2C1CCC3C2CC=C4CC(O)CCC34C KTFZDGGBFILTSA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
め要約のデータは記録されません。
Description
rostata−Hypertrophie)のさいの
排尿困難症(ロysurie)を治療するためのナフト
ビジル(Na.f topid目)の用途に関する. ナフトピジル、化学名1− (2−メトキシフエニル)
−4− (3−(ナフサ−1−−イル−オキシ)−2−
ヒドロキシ〜プロビル〕−ビベラジン(1− (2−M
eLhoxyphenyl)−4−(3−naphth
−1−yl−oxy)−2−hydroxy−prop
yl) −pipera−dln)は、西ドイツ特許第
2408804号明細書(DE−8−2408804)
の対象であって、そこには顕著な血圧降下作用を有し、
従って抗高血圧作用をもつ化合物として記載されている
.さらに、ラットにおいてデキストランで惹起させたア
ナフラキシ一様反応を抑制することが知られている. なお、ナフトピジルは次の一般式で表され、その製法及
びその塩については西ドイツ特許第2408804号明
細書の対応特許である日本特許第1.310.546号
明細書中に記載されており、公知であり、該文献はここ
で参考資料とされるべきものである.ナフトビジルの塩
には、特に非毒性の無機酸又は有機酸との付加塩がある
.このような酸としては、塩酸、臭化水素酸、硫酸、リ
ン酸、酢酸、クエン酸、酒石酸、乳酸、フマール酸、マ
レイン酸、安息香酸、アルキルスルフォン酸等を例示す
ることができる. ナフトビジルの臨床試験を行ったさいに、この化合物が
前立腺肥大において生ずる症状を軽減することを見出し
た.この症状は、排尿のさいの障害、特に夜間の尿意逼
追(Harndrang)に特徴づけられるものである
.通常、60才以上の男性がこれに関係している.従来
、これの特別な療法は確立されていない.試験的には、
植物抽出物を生薬にする作用物質あるいはβ−シトステ
リンが用いられている(Rote Liste 198
9参照).前立腺肥大に基づく排尿困難の治療のための
ナフトピジルの効力は、次に詳細に述べるは床試験から
明らかである. この試験は、全部で39人の患者で実施された.そのう
ち、37人は前立腺肥大にかかっていた.プラセボ投与
を行った1週間の予備期間の後に、ナフトビジルを1日
12.5〜100■の用量で投与した.用量は、その効
力を基準とし、1週間の間にその用量が充分な効力を奏
しない場合には、12.5■から初めて倍量に増量した
. 特に、評価の基準として次の事項を選択した。
ための腹圧及び排尿時の感覚. 評価は、次に分類した階級に基づいて行った.明らかに
改善、改善、僅かに改善、 変化なし、悪化. 全体で34人の患者が評価された.そのうち、8人が明
らかに改善され、14人が改善され、7人が僅かに改善
された.1人の患者は、変化しない挙勤を示し、その他
の4人の患者が明白な評価をすることができなかった. ナフトビジルは、特に経口的に適用される.医薬を製造
するには、ナフトピジルをそれ自体公知の方法で、適当
な薬剤の担体、芳香剤、呈味料及び着色料と混合し、例
えば錠剤または糖衣錠に戊形するかあるいは適当な助剤
を添加して水中又は例えばオリーブ油のような油に悲濁
するかして?容解する. ナフトピジルは、通常1日10■〜100■の用量で投
与される。好適には、1回の用量が10〜50■でl日
1回乃至2回投与される. この有効成分25.0■を含有する錠剤の調合を例示す
ると次のような成分を調合することである.ナフトビジ
ル 25.0■ ラクトース・IH!0 110.0■ポリ−(1−
ビニル−2−ビロリドン)MG250003.0■ 微結晶セルロース 15.0■ 高分散性(hochdisperses)SiOz1.
5 ■ ポリ−(0−カルボキシメチル)、一澱粉、Na塩4.
0■ マグネシウムーステアレート 1.5 ■ 160.0 ■ 本発明は、前立腺肥大に伴う徘尿困寵の治療に1−(2
−メトキシフェニル)−4− (3−(ナフサ−1−−
イル−オキシ)−2−ヒドロキシ−プロピル)−ピペラ
ジンを用いたものである。
Claims (2)
- (1)1−(2−メトキシフェニル)−4−〔3−(ナ
フサ−1−イル−オキシ)−2−ヒドロキシ−プロピル
〕−ピペラジン(1−(2−Methoxypheny
l)−4−〔3−naphth−1−yl−oxy)−
2−hydroxy−propyl−piperadi
n)又はその塩を有効成分とする前立腺肥大における排
尿困難症治療剤 - (2)1−(2−メトキシフェニル)−4−〔3−(ナ
フサ−1−イル−オキシ)−2−ヒドロキシ−プロピル
〕−ピペラジン(1−(2−Methoxypheny
l)−4−〔3−naphth−1−yl−oxy)−
2−hydroxy−propyl〕−piperad
in)又はその塩を有効成分として10〜50mg、通
常の担体及び助剤と共に含有する、経口投与される前立
腺肥大における排尿困難症治療剤
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3918543A DE3918543A1 (de) | 1989-06-07 | 1989-06-07 | Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie |
DE3918543.5 | 1989-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0324014A true JPH0324014A (ja) | 1991-02-01 |
JPH062673B2 JPH062673B2 (ja) | 1994-01-12 |
Family
ID=6382247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2144272A Expired - Lifetime JPH062673B2 (ja) | 1989-06-07 | 1990-06-01 | 良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途 |
Country Status (19)
Country | Link |
---|---|
US (1) | US5026706A (ja) |
EP (1) | EP0401653B1 (ja) |
JP (1) | JPH062673B2 (ja) |
KR (1) | KR0131452B1 (ja) |
AT (1) | ATE84416T1 (ja) |
AU (1) | AU625766B2 (ja) |
CA (1) | CA2017619C (ja) |
DD (1) | DD294864A5 (ja) |
DE (2) | DE3918543A1 (ja) |
DK (1) | DK0401653T3 (ja) |
ES (1) | ES2054147T3 (ja) |
GR (1) | GR3007328T3 (ja) |
HK (1) | HK46996A (ja) |
HU (1) | HU206976B (ja) |
IE (1) | IE62937B1 (ja) |
IL (1) | IL94601A (ja) |
PH (1) | PH26690A (ja) |
PT (1) | PT94268B (ja) |
ZA (1) | ZA904338B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062390A1 (fr) * | 2001-02-07 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions pharmaceutiques contre des déficiences urologiques |
US6861070B1 (en) | 1998-06-26 | 2005-03-01 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions for treating evacuatory insufficiency |
WO2013102249A1 (pt) * | 2012-01-05 | 2013-07-11 | Universidade Federal Do Rio De Janeiro-Ufrj | DERIVADOS N-FENILPIPERAZÍNICOS ANTAGONISTAS DE ADRENOCEPTORES α1A, α1D E DE RECEPTORES 5-HT1A NO TRATAMENTO DA HIPERPIASIA PROSTÁTICA BENIGNA, COMPOSIÇÕES FARMACÊUTICAS CONTENDO OS MESMOS. |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474994A (en) * | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
CA2670236C (en) | 1999-09-30 | 2012-06-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. |
-
1989
- 1989-06-07 DE DE3918543A patent/DE3918543A1/de active Granted
-
1990
- 1990-05-04 PH PH40616A patent/PH26690A/en unknown
- 1990-05-28 CA CA002017619A patent/CA2017619C/en not_active Expired - Lifetime
- 1990-05-30 DK DK90110207.9T patent/DK0401653T3/da active
- 1990-05-30 EP EP90110207A patent/EP0401653B1/de not_active Expired - Lifetime
- 1990-05-30 AT AT90110207T patent/ATE84416T1/de not_active IP Right Cessation
- 1990-05-30 DE DE9090110207T patent/DE59000748D1/de not_active Expired - Fee Related
- 1990-05-30 US US07/530,362 patent/US5026706A/en not_active Expired - Lifetime
- 1990-05-30 ES ES90110207T patent/ES2054147T3/es not_active Expired - Lifetime
- 1990-06-01 JP JP2144272A patent/JPH062673B2/ja not_active Expired - Lifetime
- 1990-06-03 IL IL9460190A patent/IL94601A/en unknown
- 1990-06-05 AU AU56282/90A patent/AU625766B2/en not_active Ceased
- 1990-06-05 PT PT94268A patent/PT94268B/pt not_active IP Right Cessation
- 1990-06-06 ZA ZA904338A patent/ZA904338B/xx unknown
- 1990-06-06 DD DD90341372A patent/DD294864A5/de not_active IP Right Cessation
- 1990-06-06 HU HU903515A patent/HU206976B/hu not_active IP Right Cessation
- 1990-06-06 IE IE201490A patent/IE62937B1/en not_active IP Right Cessation
- 1990-06-07 KR KR1019900008320A patent/KR0131452B1/ko not_active IP Right Cessation
-
1993
- 1993-03-12 GR GR920403077T patent/GR3007328T3/el unknown
-
1996
- 1996-03-14 HK HK46996A patent/HK46996A/xx not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861070B1 (en) | 1998-06-26 | 2005-03-01 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions for treating evacuatory insufficiency |
WO2002062390A1 (fr) * | 2001-02-07 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions pharmaceutiques contre des déficiences urologiques |
WO2013102249A1 (pt) * | 2012-01-05 | 2013-07-11 | Universidade Federal Do Rio De Janeiro-Ufrj | DERIVADOS N-FENILPIPERAZÍNICOS ANTAGONISTAS DE ADRENOCEPTORES α1A, α1D E DE RECEPTORES 5-HT1A NO TRATAMENTO DA HIPERPIASIA PROSTÁTICA BENIGNA, COMPOSIÇÕES FARMACÊUTICAS CONTENDO OS MESMOS. |
CN104321313A (zh) * | 2012-01-05 | 2015-01-28 | 里约热内卢联邦大学 | 为用于治疗良性前列腺增生的α1A、α1D肾上腺素能受体和5-HT1A受体的拮抗剂的N-苯基哌嗪衍生物,包含所述N-苯基哌嗪衍生物的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
PT94268A (pt) | 1991-02-08 |
ZA904338B (en) | 1991-03-27 |
DK0401653T3 (da) | 1993-03-29 |
JPH062673B2 (ja) | 1994-01-12 |
AU625766B2 (en) | 1992-07-16 |
DE3918543C2 (ja) | 1991-06-06 |
EP0401653A2 (de) | 1990-12-12 |
HU903515D0 (en) | 1990-10-28 |
IL94601A0 (en) | 1991-04-15 |
CA2017619C (en) | 1995-06-20 |
US5026706A (en) | 1991-06-25 |
PH26690A (en) | 1992-09-15 |
AU5628290A (en) | 1990-12-13 |
CA2017619A1 (en) | 1990-12-07 |
ES2054147T3 (es) | 1994-08-01 |
IE62937B1 (en) | 1995-03-08 |
KR0131452B1 (ko) | 1998-04-17 |
PT94268B (pt) | 1997-01-31 |
HK46996A (en) | 1996-03-22 |
EP0401653A3 (de) | 1991-07-17 |
HU206976B (en) | 1993-03-01 |
DE3918543A1 (de) | 1990-12-13 |
IL94601A (en) | 1994-06-24 |
GR3007328T3 (ja) | 1993-07-30 |
EP0401653B1 (de) | 1993-01-13 |
ATE84416T1 (de) | 1993-01-15 |
DE59000748D1 (de) | 1993-02-25 |
KR910000152A (ko) | 1991-01-29 |
IE902014L (en) | 1990-12-07 |
HUT54494A (en) | 1991-03-28 |
DD294864A5 (de) | 1991-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070010550A1 (en) | Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia | |
HUT72313A (en) | Pharmaceutical compositions for treating menstrual symptoms and process for their preparation | |
GB2204490A (en) | Dehydroepiandrosterone | |
JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
JPS6048924A (ja) | 骨粗鬆症治療剤 | |
Plänitz | Comparison of moxonidine and clonidine HCl in treating patients with hypertension | |
JPH0324014A (ja) | 良性前立腺肥大における排尿困難症を治療するためのナフトピジルの用途 | |
CN1142767A (zh) | 2,3-二芳基-1-苯丙吡喃衍生物在生产治疗和预防骨损失和骨质疏松症药物中的用途 | |
HOLUB et al. | Sodium and water diuresis in cirrhotic patients with intractable ascites following chemical inhibition of aldosterone synthesis | |
US3011945A (en) | Phenylcyclopropylamine -10-(omega-aminoalkyl)-phenothiazine ataractic composition | |
US4559326A (en) | Antiinflammatory compositions and methods | |
JPS62277325A (ja) | アセトアルデヒド解毒剤 | |
EP0521057A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS. | |
Pyle et al. | Clinical implications of drugs taken by our patients | |
KR100462173B1 (ko) | 요실금 예방 및 치료용 조성물 | |
JP2000503991A (ja) | 括約筋受容能力を増大させる方法 | |
JP2616845B2 (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
CZ2004719A3 (cs) | Léčivo s obsahem darifenacinu pro ošetřování nucení na močení souvisejícího s hyperaktivním měchýřem | |
WO2002043725A1 (en) | Treatment of obsessive compulsive disorder | |
CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
JP2005516925A5 (ja) | ||
JP2002080366A (ja) | 夜間頻尿症の治療剤、夜間頻尿症の予防剤 | |
JP2000514441A (ja) | 月経前症候群の1又は複数の症状を抑制するための医薬組成物の製造のための3,4―ジフェニルクロマンの使用 | |
JP2002523362A5 (ja) | ||
HU228302B1 (en) | Use of levosimendan for the treatment or prevention of coronary graft vasospasm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090112 Year of fee payment: 15 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100112 Year of fee payment: 16 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110112 Year of fee payment: 17 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120112 Year of fee payment: 18 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 19 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140112 Year of fee payment: 20 |
|
EXPY | Cancellation because of completion of term |